共 95 条
[1]
Alphs L(2014)How study designs influence comparative effectiveness outcomes: the case of oral versus long-acting injectable antipsychotic treatments for schizophrenia Schizophr Res 156 228-232
[2]
Schooler N(2004)Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease Health Qual Life Outcomes 2 12-107
[3]
Lauriello J(2013)Improving treatment adherence in your patients with schizophrenia: the STAY initiative Clin Drug Investig 33 97-874
[4]
Atkinson MJ(2002)Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting Can J Psychiatr 47 870-564
[5]
Sinha A(2003)A meta-analysis of the efficacy of second-generation antipsychotics Arch Gen Psychiatry 60 553-108
[6]
Hass SL(2016)Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics Neuropsychiatr Dis Treat 12 99-759
[7]
Cañas F(2012)Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis CNS drugs 26 733-256
[8]
Alptekin K(2010)Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study Int Clin Psychopharmacol 25 247-7
[9]
Azorin JM(2015)Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics Prog Neuro-Psychopharmacol Biol Psychiatry 58 1-44
[10]
Cook PE(2013)World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects World J Biol Psychiatry 14 2-218